GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Addex Therapeutics Ltd (XSWX:ADXN) » Definitions » Other Operating Expense

Addex Therapeutics (XSWX:ADXN) Other Operating Expense : CHF1.94 Mil (TTM As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Addex Therapeutics Other Operating Expense?

Addex Therapeutics's Other Operating Expense for the three months ended in Dec. 2023 was CHF0.68 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2023 was CHF1.94 Mil.

Addex Therapeutics's quarterly Other Operating Expense declined from Jun. 2023 (CHF0.48 Mil) to Sep. 2023 (CHF0.40 Mil) but then increased from Sep. 2023 (CHF0.40 Mil) to Dec. 2023 (CHF0.68 Mil).

Addex Therapeutics's annual Other Operating Expense increased from Dec. 2021 (CHF1.66 Mil) to Dec. 2022 (CHF1.80 Mil) and increased from Dec. 2022 (CHF1.80 Mil) to Dec. 2023 (CHF1.94 Mil).


Addex Therapeutics Other Operating Expense Historical Data

The historical data trend for Addex Therapeutics's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Addex Therapeutics Other Operating Expense Chart

Addex Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.60 -0.27 1.66 1.80 1.94

Addex Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.41 0.39 0.48 0.40 0.68

Addex Therapeutics Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF1.94 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Addex Therapeutics Other Operating Expense Related Terms

Thank you for viewing the detailed overview of Addex Therapeutics's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Addex Therapeutics (XSWX:ADXN) Business Description

Traded in Other Exchanges
Address
Chemin des Aulx 12, Plan-les-Ouates, P.O. Box 68, Geneva, CHE, 1202
Addex Therapeutics Ltd is a biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe.

Addex Therapeutics (XSWX:ADXN) Headlines

From GuruFocus

Enamine Extend Collaboration With Prominent Swiss Biotech

By Business Wire Business Wire 02-24-2021